查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
肉毒桿菌毒素市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190133

肉毒桿菌毒素市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)

Botulinum Toxin Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 114 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

肉毒桿菌毒素市場在基準年的價值為 46.5553 億美元，預計在預測期內將以 9.5% 的複合年增長率增長。

主要亮點

  • COVID-19 在大流行期間對市場增長產生了重大影響。 這是由於更嚴格的坐月子規定的實施和美容手術等非擇期手術的推遲導致肉毒桿菌毒素手術減少。 例如，根據美國整形外科學會發布的一份報告，2020 年將進行約 4,401,536 例微創 A 型肉毒桿菌毒素手術，比上一年進行的 A 型肉毒桿菌毒素手術減少 13%。
  • 手術數量的下降是由於 COVID-19 大流行導致世界各國政府實施了嚴格的規定，這對所研究的市場產生了重大影響。 然而，在大流行後放鬆對非選擇性整容手術的嚴格指導方針後，整容手術的恢復預計將有助於未來五年的市場增長。
  • 目前有多種因素正在推動全球肉毒桿菌毒素市場的增長。 其中包括對整容手術的需求不斷增加，擴大肉毒桿菌毒素治療用途的研發計劃不斷增加，以及患者對非侵入性或微創治療的偏好增加以及新產品開發。
  • 整容手術需求的增長預計將成為預測期內市場增長的主要驅動力。 美國整形外科醫師學會在 2022 年進行的一項調查指出，美國 76% 的整形外科醫生見證了整容手術的需求增加，23% 的人表示他們的業務翻了一番。 它還指出，A 型肉毒桿菌毒素將成為 2021 年至 2022 年期間患者最喜歡的微創整容手術之一。 預計對肉毒桿菌毒素治療的需求增加將有助於預測期內的市場增長。
  • 此外，擴大肉毒桿菌毒素在各種非整容手術中的治療用途，例如肌張力障礙、偏頭痛等，預計也將有助於預測期內的市場增長。 此外，肉毒桿菌毒素可用作潛在療法的各種疾病的流行預計將推動對肉毒桿菌毒素的需求，從而促進市場的增長。
  • 例如，AAN 於 2021 年 1 月發表的一篇論文指出，在美國的一項國際橫斷面隊列研究中，肌張力障礙性震顫的患病率從 36.9% 到 48.4% 不等。 此外，越來越多的使用肉毒桿菌毒素治療疾病的臨床試驗市場參與者預計將有助於市場增長。
  • 例如，2022 年 9 月，AEON Biopharma 報告了 ABP-450（prabotulinumtoxinA）6 治療成人頸肌張力障礙的 2 期臨床試驗的良好頂線結果。 預計各種市場參與者的此類臨床試驗和產品開發將有助於預測期內的市場增長。
  • 此外，為滿足對肉毒桿菌毒素不斷增長的需求而推出的創新產品有望推動市場增長。 例如，2021 年 1 月，Maypharm 推出了肉毒桿菌毒素 METOX，可以撫平因日常面部活動引起的重度至中度皺紋，是一種有效的解決方案。
  • 因此，在預測期內，化妝品和非化妝品應用中對肉毒桿菌毒素的需求增加和產品頻繁推出預計將推動市場增長。 然而，與肉毒桿菌毒素相關的副作用和缺乏支持整容手術的報銷政策預計將在預測期內抑制市場增長。

主要市場趨勢

預計在預測期內市場細分將佔很大份額

  • 預計在預測期內，礫石線段將佔據很大的市場份額。 A 型肉毒桿菌毒素可以改善礫石紋的外觀，因為它是首選的非手術治療方法。 A 型肉毒桿菌毒素是改善礫石紋外觀的最優選的非手術治療方法。 皺眉紋，也稱為“十一”，是由於在聽或讀時皺眉、做鬼臉或註意力集中而導致的眉毛之間的垂直皺紋。 這些皺紋是由控制眉毛之間運動的肌肉的規律收縮引起的。 這種肌肉的反複收縮會導致皮膚失去彈性，產生深層皺紋，當肌肉放鬆時，這些皺紋也很明顯。
  • 增加鼻唇溝的主要因素是衰老、強烈的陽光和精神壓力。 肉毒桿菌毒素有望抑制此類皺紋的發生，並有助於市場的增長。
  • 用於處理礫石管線的產品發布和批准數量的增加預計會對市場產生積極影響。 例如，2022 年 9 月，美國食品和藥物管理局 (USFDA) 批准了達西肉毒毒素 A-Ianm 注射液 (Daxxify)，用於暫時改善成人中度至重度礫石紋的外觀。 同樣，2022年6月，Galderma公佈了前兩項3期臨床試驗，顯示Lilabotulinum Toxin A改善鼻唇溝，起效快，作用持續時間長達6個月，獲得了一線結果。
  • 因此，在預測期內，對礫石紋治療的需求增加以及可有效治療礫石紋的肉毒桿菌毒素產品的推出等因素預計將促進肉毒桿菌毒素市場的增長。

預計在預測期內北美將佔據很大的市場份額

  • 在預測期內，預計北美將主導全球市場。 預計在預測期內，對整容手術的需求不斷增加、各種疾病的流行以及肉毒桿菌毒素治療應用研究和開發活動的增加等主要因素將促進該地區的市場增長。
  • 例如，根據美國骨科醫師學會 2020 年發布的一份報告，在美國的微創整容手術中，與男性相比，女性接受了大約 4,136,289 次肉毒桿菌毒素手術。超過 265,247 次肉毒桿菌毒素手術進行了治療。
  • 此外，美國整形外科醫師學會 (ASPS) 於 2022 年進行的一項調查顯示，31-45 歲的患者最有可能想要使用 A 型肉毒桿菌毒素進行整容手術。 預計這種肉毒桿菌毒素治療的採用率上升也將在預測期內推動市場增長的需求。
  • 此外，越來越多的化妝品和非化妝品應用的產品發布和產品批准有望促進市場增長。 例如，同樣在 2022 年 3 月，Aquavit Pharmaceuticals, Inc 向食品和藥物管理局提交了一項研究，以批准一種新的肉毒桿菌毒素藥物 (DTX-021)。 DTX-021 是一種 A 型肉毒桿菌毒素製劑，用於治療中度至重度灰色線。 同樣，2021 年 4 月，Aquavit Holdings LLC 獲得了在美國和加拿大註冊、營銷和商業化肉毒桿菌毒素（DTX-021）的獨家許可。
  • 因此，美容程序需求不斷增長、主要市場參與者的存在以及產品頻繁發布等因素預計將促進該地區的市場增長。

競爭格局

由於存在多個市場參與者，肉毒桿菌毒素市場較為分散。 競爭格局包括對一些具有市場份額的國際和本地公司的分析。 市場參與者包括 Galderma、Evolus, Inc.、Merz Pharma GmbH & Co. KGaA、AbbVie Inc.（Allergan）和 Ipsen Pharma。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 三個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動力
    • 對整容手術的需求增加
    • 加強研發計劃以擴大肉毒桿菌毒素的治療用途
  • 市場製約因素
    • 與肉毒桿菌毒素相關的副作用
    • 缺乏支持美容治療的報銷政策
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 通過使用
    • 化妝品用途
      • 礫石線
      • 外眼線（魚尾紋）
      • 額頭皺紋
      • 其他美容用途
    • 非美容應用
      • 肌張力障礙
      • 慢性偏頭痛
      • 眼科疾病
      • 其他非化妝品應用
  • 最終用戶
    • 水療/美容中心
    • 診所和醫院
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Merz Pharma GmbH & Co. KGaA
    • AbbVie Inc.（Allergan）
    • Evolus, Inc.
    • Revance Therapeutics Inc.
    • HUGEL, Inc.
    • Ipsen Pharma
    • US WorldMeds LLC
    • Medytox
    • Eisai
    • Hugh Source International
    • Galderma
    • Daewoong Pharmaceuticals

第七章市場機會與未來趨勢

簡介目錄
Product Code: 67009

The botulinum toxin market was valued at USD 4,655.53 million in the base year, and it is expected to register a CAGR of 9.5% during the forecast period.

Key Highlights

  • COVID-19 had a significant impact on the growth of the market during the pandemic period. This was due to the reduction of botulinum toxin procedures due to the imposition of strict lockdown restrictions and the postponement of non-elective surgeries such as cosmetic surgeries. For instance, according to the report published in the American Society of Plastic Surgeons, around 4,401,536 Botulinum Toxin Type A minimally-invasive procedures were performed in 2020, a 13% decrease from the Botulinum Toxin Type A procedures performed in the previous year.
  • The decline in the number of surgeries was due to the strict regulations imposed by governments across different countries due to the COVID-19 pandemic, which highly affected the studied market. However, the resumption of cosmetic surgeries after the relaxation of strict guidelines on non-elective aesthetic procedures during the post-pandemic situations is expected to contribute to the market's growth over the coming five years.
  • Various factors are currently driving the growth of the global botulinum toxin market. These include the increasing demand for aesthetic procedures, growing research and development initiatives to expand the therapeutic applications of botulinum toxin, and growing patient preference for non-invasive or minimal treatments coupled with novel product development.
  • The increasing demand for aesthetic procedures is expected to be the major driver for the market's growth over the forecast period. The survey conducted by the American Society of Plastic Surgeons in 2022 mentioned that in United States, 76% of plastic surgeons witnessed increased demand for cosmetic procedures and 23% reported that their business has doubled. The report also mentioned that Botulinum Toxin Type A is one of the top minimally invasive cosmetic procedures among patients during 2021-2022. Such increasing demand for botulinum toxin procedures is expected to contribute to the market's growth over the forecast period.
  • Also, growing applications for the therapeutic usage of botulinum toxin in various non-cosmetic procedures such as dystonia, migraine, and others are expected to contribute to the growth of the market over the forecast period. Moreover, the prevalence of various disorders in which the botulinum toxin can be used as the potential therapy is expected to drive the demand for the botulinum toxin, thereby contributing to the market's growth.
  • For instance, an article published by AAN in January 2021 mentioned that the prevalence of dystonia tremor in the international cross-sectional cohort study varied from 36.9% to 48.4% in United States. Also, the increasing clinical trials market player for treating diseases using botulinum toxin is expected to contribute to the market's growth.
  • For instance, in September 2022, AEON Biopharma reported positive topline results from the phase-2 clinical trial of ABP-450 (prabotulinumtoxinA) in 6treatment of cervical dystonia in adults. Such clinical trials and product development activities by various market players are expected to contribute to the market's growth over the forecast period.
  • Furthermore, innovative product launches to meet the growing demand for botulinum toxin are expected to boost the market's growth. For instance, in January 2021, Maypharm launched a botulinum toxin, METOX, which is an effective solution for smoothing any wrinkles from severe to moderate caused by daily active facial movements.
  • Thus, the increasing demand for botulinum toxin in cosmetic and non-cosmetic applications and frequent product launches are expected to drive the market's growth over the forecast period. However, adverse effects associated with botulinum toxin and the lack of reimbursement policies supporting cosmetic procedures are expected to restrain the market's growth over the forecast period.

Key Market Trends

Glabellar Lines Segment is Expected to Hold Significant Share in the Market Over the Forecast Period

  • The glabellar lines segment is expected to hold a significant market share over the forecast period. The botulinum toxin- A is the most preferred non-surgical treatment to improve the appearance of glabellar lines. The glabellar lines, also called the 'eleven', are the vertical lines that develop between the eyebrows due to frowning, scowling, or merely focusing while listening or reading. These lines occur due to regular and repeated muscle contractions that control the movement between the eyebrows. These repeated movements cause a loss of skin elasticity, resulting in the formation of deep wrinkles, which can even be seen when the muscle is relaxed.
  • The major factors leading to increased glabellar lines are natural aging, exposure to harsh sunlight, and mental stress. Such occurrences of glabellar lines are expected to contribute to the demand for botulinum toxin, thereby contributing to market growth.
  • The increasing launch of products and approvals for treating glabellar lines is expected to impact the market positively. For instance, in September 2022, United States Food and Drug Administration (USFDA) approved daxibotulinumtoxinA-Ianm injection (Daxxify) to temporarily improve the appearance of moderate to severe glabellar lines in adults. Similarly, in June 2022, Galderma obtained topline results from two phase-3 clinical studies demonstrating that RelabotulinumtoxinA improves glabellar lines with a rapid onset of action and a long duration of up to six months.
  • Thus, the factors such as rising demand for the treatment of glabellar lines and the launch of effective botulinum toxin products for the treatment of glabellar lines are expected to contribute to the growth of the botulinum toxin market during the forecast period.

North America is Expected to Hold Significant Share in the Market Over the Forecast Period

  • North America is expected to dominate the global market over the forecast period. The major factors such as rising demand for aesthetic procedures, the prevalence of various disorders, and growing research and development activities for the therapeutic applications of botulinum toxin are expected to contribute to the growth of the market over the forecast period in this region.
  • For instance, according to the report published in the American Society of Plastic Surgeons in 2020, among cosmetic minimally-invasive procedures, there were around 4,136,289 botulinum toxin procedures performed on females and over 265,247 botulinum toxin procedures performed on males in United States.
  • Similarly, a survey conducted by the American Society of Plastic Surgeons (ASPS) in 2022 revealed that patients aged 31- 45 years most commonly seek botulinum toxin type A cosmetic procedures. Such rising adoption of botulinum toxin procedures is also expected to drive the demand for the growth of the market over the forecast period.
  • Additionally, the increasing product launches and product approvals for cosmetic and non-cosmetic applications are expected to contribute to the growth of the market. For instance, Also, in March 2022, Aquavit Pharmaceuticals, Inc submitted its investigation of a New drug for botulinum toxin (DTX-021) to the Food and Administration for approval. The DTX-021 is a botulinum toxin type A drug intended for the treatment of moderate to severe glabellar lines. Similarly, in April 2021, Aquavit Holdings LLC acquired an exclusive license to register, market, and commercialize a botulinum toxin (DTX-021) in United States and Canada.
  • Hence, the factors such as rising demand for aesthetic procedures, the presence of major market players, and frequent product launches are expected to contribute to the growth of the market in this region.

Competitive Landscape

The botulinum toxin market is moderately fragmented in nature due to the presence of several market players. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares. Major companies in the market are Galderma, Evolus, Inc., Merz Pharma GmbH & Co. KGaA, AbbVie Inc. (Allergan), and Ipsen Pharma, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Demand for Aesthetic Procedures
    • 4.2.2 Growing Research and Development Initiatives to Expand the Therapeutic Applications of Botulinum Toxin
  • 4.3 Market Restraints
    • 4.3.1 Adverse effects Associated with Botulinum Toxin
    • 4.3.2 Lack of Reimbursement Policies Supporting Cosmetic Procedures
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Application
    • 5.1.1 Cosmetic Applications
      • 5.1.1.1 Glabellar lines
      • 5.1.1.2 Lateral canthal lines (crow's feet)
      • 5.1.1.3 Forehead Lines
      • 5.1.1.4 Other Cosmetic Applications​
    • 5.1.2 Non-Cosmetic Applications
      • 5.1.2.1 Dystonia
      • 5.1.2.2 Chronic migraine
      • 5.1.2.3 Ophthalmologic disorders
      • 5.1.2.4 Other Non-cosmetic Applications
  • 5.2 By End User
    • 5.2.1 Spas and Beauty Centers
    • 5.2.2 Clinics and Hospitals
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Merz Pharma GmbH & Co. KGaA
    • 6.1.2 AbbVie Inc. (Allergan)
    • 6.1.3 Evolus, Inc.
    • 6.1.4 Revance Therapeutics Inc.
    • 6.1.5 HUGEL, Inc.
    • 6.1.6 Ipsen Pharma
    • 6.1.7 US WorldMeds LLC
    • 6.1.8 Medytox
    • 6.1.9 Eisai
    • 6.1.10 Hugh Source International
    • 6.1.11 Galderma
    • 6.1.12 Daewoong Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS